Home › Cancer (all types) › NCT07327489
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RecruitingObservational study
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Able and willing to provide informed consent for participation 2. Age ≥18 years at time of consent. 3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy. 4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment. Exclusion Criteria: 1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment. 2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients. 3. Pregnant person(s).
About the study
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
What is being tested
- Biopsy (procedure)
Sponsor: Elephas · Participants: 2,000 · Started: Apr 14, 2025
Contact the study team
Official record on ClinicalTrials.gov — NCT07327489
Locations in the U.S.
| Arkansas | Mercy Hospital - FTS, Fort Smith |
| Maryland | Frederick Health Hospital, Frederick |
| Missouri | Mercy Hospital - SPG, Springfield Mercy Hospital - South, St Louis Mercy Hospital -STL, St Louis |
| Oklahoma | Mercy Hospital - OKC, Oklahoma City |
| Texas | JPS Health Network, Forth Worth Baylor Scott and White Biorepository, Temple (Not yet recruiting) |
Conditions
- Cancer (all types)
- Bladder Cancer
- Triple-Negative Breast Cancer
- Colorectal Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- Non-Small Cell Lung Cancer
- Skin Cancer
- Melanoma
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.